contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


coegin-pharma-ab-publishes-annual-report-for-the-financial-year-2024

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Coegin Pharma is a Swedish biotechnology company with dermacosmetic projects for hair growth and skin pigmentation, as well as drug candidates for the treatment of heart attacks and leukemia. What the projects have in common is that they are based on patented technology platforms and collaborations with researchers and academics internationally. Coegin Pharma has its headquarters in Lund.

Coegin Pharma

Coegin Pharma hereby announces that the Annual Report for 2024 is available for download on Coegin Pharma's website, http://www.coeginpharma.com/en. The Annual Report is also attached as a PDF...

<div class="bequoted-body">Coegin Pharma hereby announces that the Annual Report for 2024 is available for download on Coegin Pharma's website, <a href="http://www.coeginpharma.com/en">http://www.coeginpharma.com/en</a>. The Annual Report is also attached as a PDF to this press release. As previously announced, the Annual General Meeting will be held on 22 May 2025.2024 marked the beginning of an exciting new phase for Coegin Pharma. The company has laid a solid foundation to become a global player in science-based cosmetic solutions for hair growth and skin pigmentation. The company's innovations are also very well aligned with the beauty-focused side of the longevity megatrend - which is not just about living longer, but about living longer with good health, energy, and wellbeing. With this foundation in place, the company is now preparing for a historic milestone: the launch of the first hair growth product based on Follicopeptide.With a focus on the global market launch of Follicopeptide, the key activities moving forward are the ongoing production scale-up and partnering activities with key global, regional, and/or commercial partners through business development agreements. Discussions with potential global and regional partners are ongoing.The auditor's statement regarding the material uncertainty related to the going concern assumption in the auditor's report is based on the fact that Coegin Pharma is a growth company primarily funded through external capital. The Board has also initiated efforts to explore various options for securing new financing. The Board's assessment is that it is likely that measures will be implemented, and that continued liquidity can be secured. Without additional capital, the company is expected to be able to finance its ongoing operations with existing cash at least into the fourth quarter of 2025.For further information, please contact: Jens Eriksson, CEO Email: info@coeginpharma.comThis document is a translation of the original Swedish press release. In case of any discrepancies, the Swedish version shall prevail.About Coegin Pharma Coegin Pharma is a Swedish biotech company primarily focused on peptide-based premium products for hair growth and skin pigmentation. The goal is to commercialise a hair growth product series by the end of 2025, followed by a skin pigmentation product in 2026.Coegin&nbsp;Pharma's share is listed on&nbsp;NGM&nbsp;Nordic SME and dual-listed on Börse Stuttgart, and the company has a registered office in Lund, Sweden.&nbsp;For more information, please visit: <a href="http://www.coeginpharma.com/en">coeginpharma.com/en</a></div><div class="bequoted-files">Attached files<a rel="noopener" href="https://cdn.bequoted.com/media/1/aa2728cc-28ba-434c-ad10-75cd7bdc753e/250429-Press-release.pdf">250429-Press-release.pdf</a> <a rel="noopener" href="https://cdn.bequoted.com/media/1/0e58e94d-a708-4429-aa10-2ccbb3f3aff4/Annual-report-2024.pdf">Annual-report-2024.pdf</a> </div>